Why Are Steroids Contraindicated in Corneal Ulcers?

Steroids are contraindicated in corneal ulcers primarily because they suppress the local immune defenses that the eye depends on to fight infection. When the cornea is actively infected by bacteria, fungi, viruses, or parasites, applying a corticosteroid can allow the pathogen to replicate unchecked, deepen the ulcer, and push a treatable condition toward permanent vision loss or even perforation of the eye. The picture is more nuanced than a blanket ban, though, because the largest clinical trial ever conducted on the question found that in certain bacterial infections, carefully timed steroids may actually help.

How Steroids Undermine the Corneal Immune Response

The cornea is one of the few tissues in the body that is normally transparent, and maintaining that transparency requires a tightly regulated immune environment. When an infection takes hold, immune cells rush to the site, releasing inflammatory molecules that help kill the invading organism. Corticosteroids work by broadly dialing down this response. They reduce the recruitment and infiltration of inflammatory cells and suppress the proliferative response of key immune cells by dampening signaling molecules that coordinate the defense. In animal models, prednisolone alone suppressed the infiltration of specialized immune cells by roughly three-quarters after corneal injury.¹

That degree of immune suppression is useful after a corneal transplant, where the goal is to prevent the body from rejecting foreign tissue. But in an active infection, suppressing the immune response by that magnitude can be catastrophic. The very cells that the steroid is blocking are the ones responsible for containing and killing the pathogen. Strip them away, and the infection expands freely.

Fungal Infections and Why Steroids Are Especially Dangerous

Fungal keratitis is the scenario where steroids pose the clearest danger. Prolonged use of topical corticosteroids has been consistently described as worsening fungal corneal infections, through two mechanisms working in tandem: local immunosuppression and a disturbance in the normal microbial flora of the eye’s surface.² In animal studies, Candida albicans proliferated significantly more in eyes treated with dexamethasone (a potent steroid) compared to untreated controls. Not only did the fungus grow more aggressively, but the steroid also inhibited the formation of neutrophil extracellular traps, a recently discovered immune mechanism where neutrophils cast web-like structures to physically ensnare and kill microbes.²

Researchers have even used corticosteroids deliberately to establish animal models of fungal keratitis, because applying steroids to an eye before inoculating it with fungal organisms reliably produces a robust infection. That detail alone tells you something about how powerfully steroids tip the balance in favor of the fungus. In clinical practice, fungal keratitis already carries a worse prognosis than bacterial keratitis, and adding steroids to the mix makes an already difficult infection harder to control.

Herpes Simplex and Unchecked Viral Replication

Topical corticosteroids are strictly contraindicated in active herpes simplex virus (HSV) epithelial keratitis. The virus replicates within the surface cells of the cornea, and the immune system’s ability to contain it depends on a functional local inflammatory response. When that response is suppressed by steroids, the virus replicates without restraint. The clinical consequences can be dramatic: what starts as a small branching (dendritic) ulcer can spread into a large geographic or amoeboid ulcer, and in severe cases the cornea can melt or perforate.³

There is a subtlety here that trips up even experienced clinicians. Steroids are actually used in the deeper, stromal form of herpes keratitis, where the damage comes from the immune response itself rather than from active viral replication. In that situation, suppressing inflammation with steroids (under antiviral cover) can preserve corneal clarity. But in epithelial disease, where the virus is actively multiplying on the surface, steroids accelerate destruction. Getting the distinction right is essential, and getting it wrong can cost someone their vision.

Acanthamoeba and Parasitic Keratitis

Acanthamoeba keratitis is a rare but devastating parasitic infection, typically linked to contact lens wear and exposure to contaminated water. A rabbit model demonstrated that topical corticosteroids aggravated Acanthamoeba keratitis in corneas co-infected with bacteria, leading to more severe disease regardless of whether the steroids were applied early or with a delay.⁴ This matters because Acanthamoeba infections are frequently misdiagnosed at first as bacterial or herpetic keratitis, and patients may already be on steroids by the time the correct diagnosis is made. Every day of steroid use during an unrecognized Acanthamoeba infection deepens the trouble.

Delayed Wound Healing

Even when infection is controlled, steroids slow down the cornea’s ability to repair itself. The surface layer of the cornea (the epithelium) must regrow to close an ulcer, and corticosteroids delay this reepithelialization. A retrospective study of 313 cases of bacterial keratitis found that adjunctive topical steroid therapy was associated with longer healing times, particularly in infections caused by coagulase-negative Staphylococcus and Pseudomonas aeruginosa.⁵

The delay in healing creates a practical problem beyond the infection itself. An open epithelial defect is a gateway for secondary infections and continued stromal damage. Matrix metalloproteinases, enzymes that break down corneal tissue, remain active as long as the wound is open. Corticosteroids can paradoxically help suppress some of this enzymatic damage, which is one argument in their favor, but the trade-off is that the wound stays open longer.⁶ Whether the anti-inflammatory benefit outweighs the slower healing depends on the specific clinical situation, which is exactly why the decision to use steroids in corneal ulcers is not a simple one.

What the Largest Clinical Trial Actually Found

The most rigorous evidence on steroids in corneal ulcers comes from the Steroids for Corneal Ulcers Trial (SCUT), a randomized controlled trial of 500 patients with bacterial keratitis. The headline result surprised many ophthalmologists: overall, topical corticosteroid drops were neither significantly helpful nor significantly harmful. At three months, there was no meaningful difference between the steroid and placebo groups in visual acuity, scar size, time to reepithelialization, or rate of corneal perforation.⁷

But the subgroup analyses told a more interesting story. Patients who started with the worst vision (counting fingers or worse) gained about two lines of visual acuity with steroids compared to placebo. Patients with centrally located ulcers saw a similar benefit.⁷ At 12 months, patients with non-Nocardia bacterial ulcers who received steroids had about one line better visual acuity than those who got placebo. Nocardia infections, on the other hand, did worse with steroids, showing larger scars at 12 months.⁸

The SCUT also suggested that timing matters. The subgroup data pointed toward a benefit when steroids were started within two to three days of beginning antibiotic therapy, particularly for Pseudomonas infections and centrally located ulcers with poor initial vision.⁹ These findings do not mean steroids are broadly recommended. They mean the picture is more complicated than “never use steroids in a corneal ulcer.” For confirmed bacterial infections where the organism is known, the infection is responding to antibiotics, and the clinical scenario matches one of the favorable subgroups, some specialists will cautiously add steroids. For everything else, and especially when the pathogen is unknown, the traditional contraindication holds.

The Diagnostic Trap

One of the strongest practical arguments against steroids in corneal ulcers has less to do with pharmacology and more to do with diagnostic uncertainty. When someone presents with an angry, red, painful eye and a corneal infiltrate, the cause is not always obvious. Bacterial, fungal, viral, and parasitic infections can look similar in the early stages. Culture results take days. And if the wrong guess is made, steroids can turn a manageable infection into a vision-threatening emergency.

A study examining cases where topical corticosteroids were prescribed for keratitis before a culture-proven diagnosis found that this practice was harmful when Acanthamoeba or fungal keratitis was involved, precisely because these organisms are resistant to standard antibiotic drops. Keratitis that does not respond to empirical antibiotic therapy is more likely to be fungal or parasitic, and adding steroids at that point accelerates the disease. The authors emphasized that microbiological evidence, along with ruling out herpetic stromal keratitis, is needed before prescribing topical corticosteroids for any suspected infectious keratitis.¹⁰

This is why the traditional teaching is conservative. In a world where diagnostic certainty came quickly and easily, steroids could be used more selectively. In the real world, where a primary care doctor or pharmacist may reach for a steroid drop to calm a red eye before anyone has scraped the cornea for cultures, the blanket warning against steroids in corneal ulcers serves a protective function.

The Problem With Over-the-Counter Steroid Drops

In many parts of the world, topical steroid eye drops are available without a prescription or are dispensed by pharmacists for nonspecific eye complaints. This creates a dangerous scenario. A patient with an early herpetic or fungal ulcer, which may initially look like a simple red eye, applies steroid drops and feels better for a day or two as the inflammation quiets. But the underlying infection accelerates. By the time they see a specialist, the ulcer may have spread dramatically. Surveys of pharmacists have shown that awareness of these risks is inconsistent, and over-the-counter dispensing of topical eye steroids for external ocular inflammation continues to be a significant concern in public health.¹¹

Alternatives for Controlling Corneal Inflammation

Given the risks of steroids, clinicians often reach for other tools to manage the inflammation that accompanies corneal ulcers. Non-steroidal anti-inflammatory eye drops such as ketorolac, bromfenac, nepafenac, and diclofenac can reduce pain and inflammation without the immunosuppressive effects that make steroids dangerous in infections.¹⁴ These drops are not without their own concerns (rare reports of corneal melting exist with some NSAIDs, particularly diclofenac), but they do not suppress immune cell recruitment the way steroids do.

Tetracyclines, especially doxycycline taken orally, are used as adjunctive agents to reduce the activity of matrix metalloproteinases, the enzymes that chew through corneal tissue during inflammation. By inhibiting these enzymes, doxycycline can limit the collateral damage from the inflammatory response without broadly shutting down immune defenses.⁶

Regenerative Approaches for Severe or Persistent Ulcers

When corneal ulcers persist despite treatment or leave behind significant tissue loss, regenerative therapies offer options that steroids cannot. Autologous serum eye drops, made from the patient’s own blood, contain growth factors and other molecules that promote epithelial healing. These drops have shown effectiveness in neurotrophic corneal ulcers, a type of non-healing ulcer caused by loss of corneal nerve function.¹⁵

Amniotic membrane transplantation, where a thin sheet of human amniotic tissue is placed over the damaged cornea, serves as both a biological bandage and a source of anti-inflammatory and growth-promoting factors. For deep corneal ulcers after herpes, multilayered amniotic membrane grafts have been found more effective than serum drops alone.¹⁵ More recently, combining both approaches, using autologous serum drops after amniotic membrane transplantation, has been shown to improve visual acuity and corneal clarity beyond what either therapy achieves on its own.¹⁶ These therapies represent a shift in thinking: rather than simply suppressing the immune response with steroids and hoping the cornea recovers, they actively support the tissue’s own repair mechanisms.

1
PubMed Central. COMPARISON OF TOPICAL INTERLEUKIN-1 VS TUMOR NECROSIS FACTOR-ALPHA BLOCKADE WITH CORTICOSTEROID THERAPY ON MURINE CORNEAL INFLAMMATION, NEOVASCULARIZATION, AND TRANSPLANT SURVIVAL
2
PubMed Central. Topical Corticosteroids and Fungal Keratitis: A Review of the Literature and Case Series
3
PubMed Central. The three faces of herpes simplex epithelial keratitis: a steroid-induced situation
4
Scientific Reports. Corticosteroid eye drop instillation aggravates the development of Acanthamoeba keratitis in rabbit corneas inoculated with Acanthamoeba and bacteria
5
Asia-Pacific Journal of Ophthalmology. Topical Steroids as Adjunctive Therapy for Bacterial Keratitis: Evidence From a Retrospective Case Series of 313 Cases
6
ScienceDirect. The role of matrix metalloproteinases in infectious corneal ulcers
7
JAMA Ophthalmology. Corticosteroids for Bacterial Keratitis: The Steroids for Corneal Ulcers Trial (SCUT)
8
PubMed Central. The Steroids for Corneal Ulcers Trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial
9
PubMed Central. Role of steroids in the treatment of bacterial keratitis
10
PubMed Central. Topical Corticosteroids for Infectious Keratitis Before Culture-Proven Diagnosis
11
Kerala Journal of Ophthalmology. Knowledge attitude and practice regarding “over the counter” prescription of topical eye steroid among the pharmacists/medical shopkeepers
12
PubMed. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts
13
ScienceDirect. Science and strategy for preventing and managing corneal ulceration
14
PubMed Central. Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets
15
PubMed. A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis
16
PubMed Central. Effect of autologous serum after amniotic membrane transplantation for persistent corneal ulcers